SCLXW Company Profile and Key Details
NASDAQ : SCLXW
Scilex
$0.16
-0.019-10.56%
At Close 4:00 PMPrice Chart
Stock Price Today
Scilex Holding Company (SCLXW) stock declined over -10.56%, trading at $0.16 on NASDAQ, down from the previous close of $0.18. The stock opened at $0.18, fluctuating between $0.14 and $0.19 in the recent session.
Stock Snapshot
0.18
Prev. Close
59.32M
Market Cap
0.1352
Day Low
-0.01
P/E Ratio
-32.56651
EPS (TTM)
-0.21
Cash Flow per Share
0.18
Open
8.49M
Number of Shares
0.1901
Day High
73.54%
Free Float in %
-1.73
Book Value
8.28K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 06, 2026 | 0.18 | 0.19 | 0.14 | 0.16 | 8.28K |
| Jul 02, 2026 | 0.17 | 0.18 | 0.15 | 0.18 | 5.01K |
| Jul 01, 2026 | 0.15 | 0.19 | 0.14 | 0.16 | 11.58K |
| Jun 30, 2026 | 0.12 | 0.13 | 0.08 | 0.13 | 17.35K |
| Jun 29, 2026 | 0.12 | 0.12 | 0.12 | 0.12 | 231 |
| Jun 26, 2026 | 0.13 | 0.13 | 0.12 | 0.12 | 1.01K |
| Jun 25, 2026 | 0.15 | 0.15 | 0.13 | 0.13 | 1.26K |
| Jun 24, 2026 | 0.19 | 0.19 | 0.19 | 0.19 | 5 |
| Jun 23, 2026 | 0.19 | 0.19 | 0.13 | 0.16 | 150 |
| Jun 22, 2026 | 0.13 | 0.14 | 0.13 | 0.14 | 12 |
| Jun 18, 2026 | 0.16 | 0.16 | 0.13 | 0.13 | 81 |
| Jun 17, 2026 | 0.17 | 0.17 | 0.15 | 0.17 | 1.66K |
| Jun 16, 2026 | 0.21 | 0.21 | 0.17 | 0.17 | 2.22K |
| Jun 15, 2026 | 0.19 | 0.21 | 0.19 | 0.21 | 721 |
| Jun 12, 2026 | 0.17 | 0.17 | 0.17 | 0.17 | 575 |
| Jun 11, 2026 | 0.17 | 0.17 | 0.17 | 0.17 | 4.28K |
| Jun 10, 2026 | 0.14 | 0.17 | 0.14 | 0.17 | 5.72K |
| Jun 09, 2026 | 0.14 | 0.14 | 0.14 | 0.14 | 1.51K |
| Jun 08, 2026 | 0.17 | 0.17 | 0.15 | 0.15 | 706 |
| Jun 04, 2026 | 0.16 | 0.16 | 0.16 | 0.16 | 41 |
Contact Details
About Company
Scilex Holding Company operates as a biopharmaceutical firm primarily engaged in creating and distributing non-opioid treatments for individuals suffering from acute and chronic pain conditions. Its flagship product, ZTlido 1.8%, is a prescription-only topical lidocaine formulation designed to alleviate neuropathic pain, specifically that associated with post-herpetic neuralgia, a type of nerve pain occurring after a shingles infection. The company's development pipeline also features SP-102, known as SEMDEXA, a viscous corticosteroid gel administered via epidural injections. This candidate is currently in Phase 3 clinical trials, targeting lumbosacral radicular pain. Another investigational drug, SP-103, aims to treat low back pain and is progressing through Phase 2 clinical trials. Additionally, SP-104, an innovative low-dose, delayed-release naltrexone hydrochloride formulation, is in Phase 1 clinical development for managing fibromyalgia. Scilex Holding Company is headquartered in Palo Alto, California, and functions as a subsidiary of Sorrento Therapeutics, Inc.
Company Information
| Employees | 115 |
| Beta | 1.71 |
| Sales or Revenue | $46.74M |
| 5Y Sales Change% | 1.407% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Stock Peers
AMGN
12.82+3.55%
Amgen Inc.$374.15BIIB6.38+3.04%
Biogen Inc.$216.12GILD5.3+4.21%
Gilead Sciences, Inc.$131.27HZNP00
Horizon Therapeutics Public Limited Company$116.30SNY1.53+3.68%
Sanofi$43.16SCLX-0.07-0.89%
Scilex Holding Company$7.81GRFS0.08+1.13%
Grifols, S.A.$7.16MIRA-0.0025-0.26%
MIRA Pharmaceuticals, Inc.$0.94CTOR-0.0239-3.39%
Citius Oncology, Inc.$0.68Company Overview
Scilex Holding Company (NASDAQ:SCLXW) closed at $0.16 USD, losing -$0.02 (-10.56%) from the previous close of $0.18. The stock is currently mid-range between its 52-week high and low $0.14 and $0.19. With a market capitalization of about $59.32 million, Scilex Holding Company is classified as a micro-cap and shows higher-than-market volatility (beta ~1.73). Key stats such as the average daily volume over the past year has been around 17.48 thousand shares, volume is running light vs its 52-week average. Headquartered in Palo Alto, CA, Scilex Holding Company operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Henry H. Ji, the company employs approximately 115 people and listed since March 05, 2021. Scilex Holding Company operates as a biopharmaceutical firm primarily engaged in creating and distributing non-opioid treatments for individuals suffering from acute and chronic pain conditions.
Technical Performance
Average 10-day trading volume of 7.04 thousand shares is slightly above the 3-month average of 5.41 thousand, indicating heightened recent market interest.
Valuation Metrics
Scilex Holding Company trades at a P/E ratio of -0.2, slightly below the S&P 500 average, with a price-to-sales ratio of 1.96 and a price-to-book ratio of -0.22 indicating negative book value, which may reflect financial stress. The P/FCF stands at -10.06, also above market averages.
Dividend & Fair Value
Dividend and splits history remains an important factor for investors monitoring long-term returns.
Earnings & Analyst Outlook
Scilex Holding Company earnings surprise history is a mixed track record. The quarter that ended May 20, 2026, missed forecasts by 1761.84%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 300.97% in August 13, 2025.
Financial & Profitability Overview
On valuation metrics, Scilex trades at a P/E of -0.22, P/S of 2.12 and P/B of -0.23. Liquidity is tight, with a current ratio of 0.08 and quick ratio of 0.07. Operationally, the company’s inventory turnover is 3.36 and cash conversion cycle is -2001.02 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -0.43, supported by a cash flow-to-debt ratio of -0.03.
Quarterly Financial Highlights
The company ended the quarter with $3.92M in cash and short-term investments, a total debt of $128.46M, and net debt of $124.54M. Total assets were $101.31M, with equity of - $172.94M. Financials further reflected weakness, with operating cash flow of - $20.71M, free cash flow of - $21.04M, and capital expenditures of - $330.00K.
Price Forecast & Outlook
Our AI price prediction model suggests that Scilex Holding Company stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 172.22%, with price expected at $0.49 by November 24, 2023, within a range of $0.40 to $0.58
Key Takeaways
Scilex Holding Company (NASDAQ:SCLXW) shares are flat 2.43% year-to-date Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Scilex Holding Company trading at a premium to the broader market with a P/E of -0.2.
Frequently Asked Questions
What is the current Scilex Holding Company (SCLXW) stock price?
Scilex Holding Company (NASDAQ: SCLXW) stock price is $0.16 in the last trading session. During the trading session, SCLXW stock reached the peak price of $0.19 while $0.14 was the lowest point it dropped to. The percentage change in SCLXW stock occurred in the recent session was -10.56% while the dollar amount for the price change in SCLXW stock was - $0.02.
SCLXW's industry and sector of operation?
The NASDAQ listed SCLXW is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Scilex Holding Company designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of SCLXW?
Mr. Suketu D. Desai Ph.D.
Chief Technical Officer
Mr. Steven F. Lincoln J.D.
Interim Gen. Counsel & Chief Compliance Officer
Mr. Jaisim Shah
Pres, Chief Executive Officer & Director
Dr. Dmitri V. Lissin M.D.
Senior Vice President & Chief Medical Officer
Mr. Suresh K. Khemani
Senior Vice President & Chief Commercial Officer
Dr. Henry H. Ji Ph.D.
Executive Chairman
Ms. Elizabeth Adkins Czerepak M.B.A.
Executive Vice President, Chief Financial Officer, Chief Bus. Officer & Sec.
Chief Technical Officer
Mr. Steven F. Lincoln J.D.
Interim Gen. Counsel & Chief Compliance Officer
Mr. Jaisim Shah
Pres, Chief Executive Officer & Director
Dr. Dmitri V. Lissin M.D.
Senior Vice President & Chief Medical Officer
Mr. Suresh K. Khemani
Senior Vice President & Chief Commercial Officer
Dr. Henry H. Ji Ph.D.
Executive Chairman
Ms. Elizabeth Adkins Czerepak M.B.A.
Executive Vice President, Chief Financial Officer, Chief Bus. Officer & Sec.
How SCLXW did perform over past 52-week?
SCLXW's closing price is 19.08% higher than its 52-week low of $0.14 where as its distance from 52-week high of $0.19 is -16.15%.
How many employees does SCLXW have?
Number of SCLXW employees currently stands at 115.
Link for SCLXW official website?
Official Website of SCLXW is: https://www.scilexholding.com
How do I contact SCLXW?
SCLXW could be contacted at phone 650 516 4310 and can also be accessed through its website. SCLXW operates from 960 San Antonio Road, Palo Alto, CA 94303, United States.
How many shares of SCLXW are traded daily?
SCLXW stock volume for the day was 8.28K shares. The average number of SCLXW shares traded daily for last 3 months was 17.48K.
What is the market cap of SCLXW currently?
The market value of SCLXW currently stands at $59.32M with its latest stock price at $0.16 and 8.49M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep